Precision Molecular Imaging & Theranostics

Precision Molecular Imaging & Theranostics (PMIT) is a leading clinical-stage biotechnology company based in Beijing, China, specializing in the development and commercialization of targeted radiopharmaceuticals. As the specialized radiopharmaceutical arm of Xiantong Pharma, PMIT focuses on the 'theranostic' paradigm, which integrates diagnostic imaging with targeted radionuclide therapy to provide precision medicine solutions for oncology and neurology. The company's robust pipeline includes advanced candidates targeting Fibroblast Activation Protein (FAP) and Prostate-Specific Membrane Antigen (PSMA), alongside licensed global assets such as Pylarify and Amyvid. PMIT operates integrated R&D centers and GMP-compliant manufacturing facilities, positioning itself as a dominant player in the rapidly expanding nuclear medicine market in Asia. Through strategic partnerships with international leaders like Lantheus and Curium, the company continues to bring world-class molecular imaging and therapeutic agents to the Chinese healthcare system.